Navigation Links
Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor



FLEXSTATION IS A VERSATILE TOOL FOR ASSAY DEVELOPMENT AND BASIC RESEARCH

SIMPLE, RAPID EXPERIMENTAL SET-UP AND DATA ANALYSIS

DETERMINE EC50 AND IC50 VALUES

EXCELLENT FOR ASSAY DEVELOP-MENT AS DEMONSTRATED BY Z FACTOR


INTRODUCTION

Gq-coupled receptors are transmembrane proteins that are responsible for transmitting extracellular signals to the inside of the cell, which ultimately leads to changes in gene expression. Some Gq-coupled receptors can be activated through the specific binding of ligands or drugs to the extracellular domains of the protein. This interaction leads to downstream events such as mobilization of calcium from intracellular storage vesicles into the cytoplasm of the cell. Improper Gq-coupled receptor function is implicated in cancer, neurodegenerative and cardiovascular diseases. Therefore, it is important to compare receptor function in normal and disease states.

The cell line used in these studies, M1 CHO, is stably transfected with the M1 muscarinic Gqcoupled receptor1. This receptor is stimulated with carbachol, which leads to the release of calcium from the endoplasmic reticulum into the cytosol. Activation of the M1 Gq-coupled receptor can be monitored using FLEXstation in conjunction with either the calcium-sensitive fluorescent dye, Fluo-3, or the FLEXstation Calcium Assay Kit from Molecular Devices. The results demonstrate that a similar range of EC50 values is obtained for carbachol using both detection methods.


METHODS
Cells were seeded the night before the experiment at a concentration of 30,000 cells/well in a volume of 100 L per well of black walled, clear bottomed, 96-well microplates (E&K distributors, cat# 655 090). Cells were incubated either for one hour with a buffer containing 4.2 M Fluo-3 or for one-half hour with 1X Loading Buffer from the FLEXstation Calcium Assay Kit (Molecular Devices, cat#R8041) before using FLEXstation to dispense carbachol and monitor the mobilization of calcium into the cell cytosol. All experiments were performed at a final concentration of 2.5 mM probenecid in order to inhibit endogenous efflux pumps present in M1 CHO cells.


DETERMINATION OF EC50 VALUES
Cells were exposed to a range of carbachol (0 to 1 M) using half log dilutions of the agonist. Results are representative of at least four independent experiments performed over a period of at least two different days. The raw data was analyzed as Max-Min and Absolute RFU values (Figures 1, 2). The average value of replicate samples was plotted on a graph using a curve fit of four parameter, for which the C value is the concentration of drug that causes 50% of maximal response (EC50 value, see Figure 3). The EC50 values for carbachol using Fluo-3 ranged from 1939 nM, whereas it ranged from 1230 nM using the FLEXstation Calcium Assay Kit (see Figures 3 and 4).



DETERMINATION OF Z FACTOR
Cells in half of the microplate were treated with 0.5 M carbachol, while cells in the other half of the plate were treated with 1X Reagent Buffer (1X HBSS/20 mM HEPES pH 7.4). The FLEXstation Calcium Assay Kit was used to monitor carbachol-mediated calcium mobilization (Figure 5). Z factor was calculated using the formula2:

The terms sc- and sc+ denote the standard deviation of the negative control and positive control, respectively, whereas |c+ c-| denotes the absolute value of the difference in the mean of the positive control and the mean of the negative control. The Z factor obtained for FLEXstation using the FLEXstation Calcium Assay Kit was 0.65. This indicates a large separation band between the negative and positive controls and an optimized, high quality assay.


SUMMARY
FLEXstation generates highly reproducible results for calcium mobilization assays used to monitor the activity of Gq-coupled receptors (Fig. 3). First, the EC50 values obtained for carbachol were consistent between detection methods, Fluo-3 and the FLEXstation Calcium Assay Kit. Also, assays analyzed on the same day showed less than two-fold differences, and assays analyzed on different days showed less than fourfold differences, which further demonstrates the reliable performance of FLEXstation (data not shown). Lastly, the Z factor determination indicates that FLEXstation provides an excellent tool for assay development for the model system examined. In addition, other benefits include SOFTmax PRO software that makes it simple to set up the instrument and analyze the data. Moreover, the dual monochromators provide increased flexibility for assay development or basic research purposes. In conclusion, FLEXstation provides an easy-to-use, versatile tool to help basic research and assay development laboratories reach their goals.

For more detailed information, please refer to the application note Comparison of FLIPR and FLEXstation for Calcium Mobilization Assays, available for download from Molecular Devices web site at:
www.moleculardevices.com/pages/flex_lit1.html


REFERENCES
1. Buck, M. A., and C. M. Fraser. 1990. Biochem. Biophys. Res. Commun. 173: 666672.
2. Zhang , J-H., T.D.Y. Thomas, and K. R. Oldenburg. 1999. J. Biomol. Screening 4: 6773.

SALES OFFICES
USA 800-635-5577
UK +44-118-944-8000
Germany +49-89-9620-2340
Japan +81-6-6399-8211

Check our web site for a current listing of our worldwide distributors.
www.moleculardevices.com


FLEXstation is a trademark of Molecular Devices Corporation.


back to top


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Gq-coupled Receptor Assays Using FLEXstation
2. Gq-coupled receptor assays: a comparison of FLEXstation and FLIPR
3. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
4. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
5. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
6. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
7. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
8. The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR
9. The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies
10. Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
11. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):